A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jul 2024 According to an Alzheon media release, company announced its participation and discussing data of this trial in the Alzheimers Association International Conference (AAIC) in Philadelphia, held from July 28 to August 1, 2024.
25 Jun 2024 According to an Alzheon media release, the company announced two scientific publications of results from this trial showing statistically significant and clinically relevant reduction in plasma biomarkers of neurodegeneration
25 Jun 2024 Results published in the Alzheon Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com